Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neuro-oncological ventral antigen 1 (NOVA1): Implications in neurological diseases and cancers.

Literature DB >> 28394091

Neuro-oncological ventral antigen 1 (NOVA1): Implications in neurological diseases and cancers.

Yu Xin¹, Zheng Li², Heyi Zheng¹, Jeffery Ho³, Matthew T V Chan³, William K K Wu^3,4.

Abstract

Neuro-oncological ventral antigen 1 (NOVA1) is a RNA-binding protein that interacts with RNA containing repeats of the YCAY sequence. This protein is a brain-specific splicing factor regulating neuronal alternative splicing. It has been increasingly recognized as an important contributor to neurological disorders and carcinogenesis. In this review, we summarize the biological functions and pathological roles of NOVA1. The clinical implications of NOVA1 will also be discussed.

Entities: Disease Gene

Mesh：

Substances：

Year: 2017 PMID： 28394091 PMCID： PMC6529068 DOI： 10.1111/cpr.12348

Source DB: PubMed Journal: Cell Prolif ISSN： 0960-7722 Impact factor: 6.831

27 in total

1. MicroRNA-339, an epigenetic modulating target is involved in human gastric carcinogenesis through targeting NOVA1.

Authors: Bo Shen; Yan Zhang; Shaorong Yu; Yuan Yuan; Yuejiao Zhong; Jianwei Lu; Jifeng Feng
Journal: FEBS Lett Date: 2015-09-29 Impact factor: 4.124

2. The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo.

Authors: R J Buckanovich; R B Darnell
Journal: Mol Cell Biol Date: 1997-06 Impact factor: 4.272

3. Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability.

Authors: K B Jensen; B K Dredge; G Stefani; R Zhong; R J Buckanovich; H J Okano; Y Y Yang; R B Darnell
Journal: Neuron Date: 2000-02 Impact factor: 17.173

4. CLIP identifies Nova-regulated RNA networks in the brain.

Authors: Jernej Ule; Kirk B Jensen; Matteo Ruggiu; Aldo Mele; Aljaz Ule; Robert B Darnell
Journal: Science Date: 2003-11-14 Impact factor: 47.728

5. Implications of NOVA1 suppression within the microenvironment of gastric cancer: association with immune cell dysregulation.

Authors: Eun Kyung Kim; Sun Och Yoon; Woon Yong Jung; Hyunjoo Lee; Youngran Kang; You-Jin Jang; Soon Won Hong; Seung Ho Choi; Woo Ick Yang
Journal: Gastric Cancer Date: 2016-06-18 Impact factor: 7.370

6. High expression of neuro-oncological ventral antigen 1 correlates with poor prognosis in hepatocellular carcinoma.

Authors: Yi-An Zhang; Ji-Min Zhu; Jie Yin; Wen-Qing Tang; Yan-Mei Guo; Xi-Zhong Shen; Tao-Tao Liu
Journal: PLoS One Date: 2014-03-07 Impact factor: 3.240

7. TOX4 and NOVA1 proteins are partners of the LEDGF PWWP domain and affect HIV-1 replication.

Authors: Mehdi Morchikh; Monica Naughtin; Francesca Di Nunzio; Johan Xavier; Pierre Charneau; Yves Jacob; Marc Lavigne
Journal: PLoS One Date: 2013-11-27 Impact factor: 3.240

8. Partial monosomy14q involving FOXG1 and NOVA1 in an infant with microcephaly, seizures and severe developmental delay.

Authors: H Fryssira; E Tsoutsou; S Psoni; S Amenta; T Liehr; E Anastasakis; Ch Skentou; A Ntouflia; I Papoulidis; E Manolakos; N Chaliasos
Journal: Mol Cytogenet Date: 2016-08-02 Impact factor: 2.009

9. NOVA1 inhibition by miR-146b-5p in the remnant tissue microenvironment defines occult residual disease after gastric cancer removal.

Authors: Sun Och Yoon; Eun Kyung Kim; Mira Lee; Woon Yong Jung; Hyunjoo Lee; Youngran Kang; You-Jin Jang; Soon Won Hong; Seung Ho Choi; Woo Ick Yang
Journal: Oncotarget Date: 2016-01-19

10. NOVA2-mediated RNA regulation is required for axonal pathfinding during development.

Authors: Yuhki Saito; Soledad Miranda-Rottmann; Matteo Ruggiu; Christopher Y Park; John J Fak; Ru Zhong; Jeremy S Duncan; Brian A Fabella; Harald J Junge; Zhe Chen; Roberto Araya; Bernd Fritzsch; A J Hudspeth; Robert B Darnell
Journal: Elife Date: 2016-05-25 Impact factor: 8.140

10 in total

1. Reintroduction of the archaic variant of NOVA1 in cortical organoids alters neurodevelopment.

Authors: Cleber A Trujillo; Edward S Rice; Nathan K Schaefer; Isaac A Chaim; Emily C Wheeler; Assael A Madrigal; Justin Buchanan; Sebastian Preissl; Allen Wang; Priscilla D Negraes; Ryan A Szeto; Roberto H Herai; Alik Huseynov; Mariana S A Ferraz; Fernando S Borges; Alexandre H Kihara; Ashley Byrne; Maximillian Marin; Christopher Vollmers; Angela N Brooks; Jonathan D Lautz; Katerina Semendeferi; Beth Shapiro; Gene W Yeo; Stephen E P Smith; Richard E Green; Alysson R Muotri
Journal: Science Date: 2021-02-12 Impact factor: 47.728

2. Identification of NOVA family proteins as novel β-catenin RNA-binding proteins that promote epithelial-mesenchymal transition.

Authors: Shulin Tang; Yurong Zhao; Xirong He; Jiahui Zhu; Shuang Chen; Jikai Wen; Yiqun Deng
Journal: RNA Biol Date: 2020-03-04 Impact factor: 4.652

10. NOVA1 expression is associated with clinicopathological characteristics and prognosis in patients with small cell lung cancer.

Authors: Meixuan Liu; Shuangshuang Deng; Tianyu Xiao; Jinli Gao
Journal: Transl Cancer Res Date: 2020-07 Impact factor: 1.241

10 in total

Neuro-oncological ventral antigen 1 (NOVA1): Implications in neurological diseases and cancers.

1. MicroRNA-339, an epigenetic modulating target is involved in human gastric carcinogenesis through targeting NOVA1.

2. The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo.

3. Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability.

4. CLIP identifies Nova-regulated RNA networks in the brain.

5. Implications of NOVA1 suppression within the microenvironment of gastric cancer: association with immune cell dysregulation.

6. High expression of neuro-oncological ventral antigen 1 correlates with poor prognosis in hepatocellular carcinoma.

7. TOX4 and NOVA1 proteins are partners of the LEDGF PWWP domain and affect HIV-1 replication.

8. Partial monosomy14q involving FOXG1 and NOVA1 in an infant with microcephaly, seizures and severe developmental delay.

9. NOVA1 inhibition by miR-146b-5p in the remnant tissue microenvironment defines occult residual disease after gastric cancer removal.

10. NOVA2-mediated RNA regulation is required for axonal pathfinding during development.

1. Reintroduction of the archaic variant of NOVA1 in cortical organoids alters neurodevelopment.

2. Identification of NOVA family proteins as novel β-catenin RNA-binding proteins that promote epithelial-mesenchymal transition.

3. NOVA1 acts as an oncogene in melanoma via regulating FOXO3a expression.

4. Upregulation of the alternative splicing factor NOVA2 in colorectal cancer vasculature.

5. Role of global aberrant alternative splicing events in papillary thyroid cancer prognosis.

6. The expression and role of miR-181a in multiple myeloma.

7. Identification of molecular correlations of RBM8A with autophagy in Alzheimer's disease.

8. Inhibition of miR-96-5p in the mouse brain increases glutathione levels by altering NOVA1 expression.

Review 9. Alternative Splicing by NOVA Factors: From Gene Expression to Cell Physiology and Pathology.

10. NOVA1 expression is associated with clinicopathological characteristics and prognosis in patients with small cell lung cancer.